Show simple item record

dc.contributor.authorJiang, Zhong
dc.contributor.authorLohse, Christine M.
dc.contributor.authorChu, Peigou G.
dc.contributor.authorWu, Chin-Lee
dc.contributor.authorWoda, Bruce A.
dc.contributor.authorRock, Kenneth L.
dc.contributor.authorKwon, Eugene D.
dc.date2022-08-11T08:09:37.000
dc.date.accessioned2022-08-23T16:37:58Z
dc.date.available2022-08-23T16:37:58Z
dc.date.issued2008-04-17
dc.date.submitted2009-10-29
dc.identifier.citation<p>Cancer. 2008 Jun 15;112(12):2676-82. <a href="http://dx.doi.org/10.1002/cncr.23484">Link to article on publisher's site</a></p>
dc.identifier.issn0008-543X (Print)
dc.identifier.doi10.1002/cncr.23484
dc.identifier.pmid18412154
dc.identifier.urihttp://hdl.handle.net/20.500.14038/39143
dc.description.abstractBACKGROUND: Whether an oncofetal protein, IMP3, can serve as a prognostic biomarker to predict metastasis for patients with localized papillary and chromophobe subtypes of renal cell carcinomas (RCCs) was investigated. METHODS: The expression of IMP3 in 334 patients with primary papillary and chromophobe RCC from multiple medical centers was evaluated by immunohistochemistry. The 317 patients with localized papillary and chromophobe RCCs were further evaluated for outcome analyses. RESULTS: IMP3 was significantly increased in a subset of localized papillary and chromophobe RCCs that subsequently metastasized. Patients with localized IMP3-positive tumors (n=33; 10%) were over 10 times more likely to metastasize (risk ratio [RR], 11.38; 95% confidence interval [CI], 5.40-23.96; PCONCLUSIONS: IMP3 is an independent prognostic biomarker that can be used to identify a subgroup of patients with localized papillary and chromophobe RCC who are at high risk for developing distant metastasis.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=18412154&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2789394/
dc.subjectAntigens, Neoplasm
dc.subjectCarcinoma, Papillary
dc.subjectCarcinoma, Renal Cell
dc.subjectDisease-Free Survival
dc.subjectHumans
dc.subjectKidney Neoplasms
dc.subjectNeoplasm Proteins
dc.subjectRNA-Binding Proteins
dc.subjectTumor Markers, Biological
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleOncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas
dc.typeJournal Article
dc.source.journaltitleCancer
dc.source.volume112
dc.source.issue12
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/1957
dc.identifier.contextkey1050693
html.description.abstract<p>BACKGROUND: Whether an oncofetal protein, IMP3, can serve as a prognostic biomarker to predict metastasis for patients with localized papillary and chromophobe subtypes of renal cell carcinomas (RCCs) was investigated.</p> <p>METHODS: The expression of IMP3 in 334 patients with primary papillary and chromophobe RCC from multiple medical centers was evaluated by immunohistochemistry. The 317 patients with localized papillary and chromophobe RCCs were further evaluated for outcome analyses.</p> <p>RESULTS: IMP3 was significantly increased in a subset of localized papillary and chromophobe RCCs that subsequently metastasized. Patients with localized IMP3-positive tumors (n=33; 10%) were over 10 times more likely to metastasize (risk ratio [RR], 11.38; 95% confidence interval [CI], 5.40-23.96; PCONCLUSIONS: IMP3 is an independent prognostic biomarker that can be used to identify a subgroup of patients with localized papillary and chromophobe RCC who are at high risk for developing distant metastasis.</p>
dc.identifier.submissionpathoapubs/1957
dc.contributor.departmentDepartment of Pathology
dc.source.pages2676-82


This item appears in the following Collection(s)

Show simple item record